1. Home
  2. VALU vs VNDA Comparison

VALU vs VNDA Comparison

Compare VALU & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Value Line Inc.

VALU

Value Line Inc.

N/A

Current Price

$43.46

Market Cap

341.6M

Sector

Finance

ML Signal

N/A

Logo Vanda Pharmaceuticals Inc.

VNDA

Vanda Pharmaceuticals Inc.

HOLD

Current Price

$3.90

Market Cap

301.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VALU
VNDA
Founded
1931
2002
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
341.6M
301.1M
IPO Year
1995
2005

Fundamental Metrics

Financial Performance
Metric
VALU
VNDA
Price
$43.46
$3.90
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
★ $11.50
AVG Volume (30 Days)
2.2K
★ 952.0K
Earning Date
12-14-2026
10-28-2026
Dividend Yield
★ 3.36%
N/A
EPS Growth
★ 4.55
N/A
EPS
★ 0.50
N/A
Revenue
$36,257,000.00
★ $216,105,000.00
Revenue This Year
N/A
$15.16
Revenue Next Year
N/A
$35.50
P/E Ratio
$86.92
★ N/A
Revenue Growth
1.08
★ 8.72
52 Week Low
$32.00
$3.79
52 Week High
$47.00
$9.91

Technical Indicators

Market Signals
Indicator
VALU
VNDA
Relative Strength Index (RSI) 62.05 28.07
Support Level $36.25 N/A
Resistance Level $47.00 $5.37
Average True Range (ATR) 1.47 0.20
MACD -0.06 -0.01
Stochastic Oscillator 63.17 19.50

Price Performance

Historical Comparison
VALU
VNDA

About VALU Value Line Inc.

Value Line Inc is a U.S based company. It produces investment periodicals based on underlying research and makes available copyright data, including a ranking system and other information, to third parties under written agreements for use in third-party managed and marketed investment products and for other purposes. The company markets its products under brands including Value Line, the Value Line logo, The Value Line Investment Survey, Smart Research, Smarter Investing, and The Most Trusted Name in Investment Research. Its only operating segment is Publishing.

About VNDA Vanda Pharmaceuticals Inc.

Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include ASO Molecules, VQW-765, Tradipitant, and VTR-297. The maximum of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.

Share on Social Networks: